These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18559790

  • 1. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.
    Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
    [No Abstract] [Full Text] [Related]

  • 2. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K, Amoh Y, Mii S, Eto H, Iwamura M, Katsuoka K.
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract] [Full Text] [Related]

  • 3. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 4. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR, Stetson CL, Smith JL.
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract] [Full Text] [Related]

  • 5. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R.
    Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Squamous cell carcinoma in a patient receiving sorafenib].
    Adnot-Desanlis L, Bernard P, Reguiaï Z.
    Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI.
    Eur Urol; 2008 May; 53(5):917-30. PubMed ID: 18054825
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hand-foot and stump syndrome to sorafenib.
    Lai SE, Kuzel T, Lacouture ME.
    J Clin Oncol; 2007 Jan 20; 25(3):341-3. PubMed ID: 17235051
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE, Watson AC, Aronson P.
    Dermatol Online J; 2013 May 15; 19(5):18184. PubMed ID: 24011281
    [Abstract] [Full Text] [Related]

  • 20. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, Martínez-Rodríguez A, Báez-Perea JM.
    JAMA Dermatol; 2013 May 15; 149(5):624-6. PubMed ID: 23677103
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.